Elahere
(MIRVETUXIMAB SORAVTANSINE)ImmunoGen, Inc.
Usage: ELAHERE® is indicated for adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have undergone one to three prior systemic treatments. Patient selection should utilize an FDA-approved test.